Search Orphan Drug Designations and Approvals
-
Generic Name: | Autologous ex-vivo CRISPR/Cas9 engineered Wilms¿ tumor 1-specific T-cell receptor T cells |
---|---|
Date Designated: | 03/09/2022 |
Orphan Designation: | Treatment of acute myeloid leukemia |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Intellia Therapeutics, Inc. 40 Erie Street Cambridge, Massachusetts 02139 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
-